GRTX Company Profile and Key Details
Galera Therapeutics, Inc.
GRTX Stock Price Chart
Stock Price Today
Galera Therapeutics, Inc. (GRTX) stock surged +7.62%, trading at $0.05 on NASDAQ, up from the previous close of -. The stock opened at $0.04, fluctuating between $0.04 and $0.05 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Company Information
| Employees | 7 |
| Beta | 1.99 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Galera Therapeutics, Inc. (NASDAQ: GRTX) stock price is $0.05 in the last trading session. During the trading session, GRTX stock reached the peak price of $0.05 while $0.04 was the lowest point it dropped to. The percentage change in GRTX stock occurred in the recent session was 7.62% while the dollar amount for the price change in GRTX stock was $0.00.
The NASDAQ listed GRTX is part of Biotechnology industry that operates in the broader Healthcare sector. Galera Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. J. Mel Sorensen M.D.
Chief Executive Officer, Pres & Director
Mr. Christopher Degnan
Chief Financial Officer
Mr. Mark J. Bachleda M.B.A., Pharm.D.
Chief Commercial Officer
Dr. Robert A. Beardsley M.B.A., Ph.D.
Co-Founder & Chief Operating Officer
Dr. Dennis P. Riley Ph.D.
Chief Scientific Officer, Emeritus
Ms. Jennifer Evans Stacey Esq.
Chief Legal & Compliance Officer and Sec.
Ms. Andie Collier
Chief Regulatory & Quality Officer
Ms. Judy Schnyder
Senior Vice President of Clinical Operations & Data Management
Dr. Eugene P. Kennedy F.A.C.S., FACS, M.D.
Chief Medical Officer
Dr. Jon T. Holmlund M.D.
Executive Officer
GRTX's closing price is 112.38% higher than its 52-week low of $0.02 where as its distance from 52-week high of $0.29 is -84.62%.
Number of GRTX employees currently stands at 7.
Official Website of GRTX is: https://www.galeratx.com
GRTX could be contacted at phone 610 725 1500 and can also be accessed through its website. GRTX operates from 2 West Liberty Boulevard, Malvern, PA 19355, United States.
GRTX stock volume for the day was 1.15K shares. The average number of GRTX shares traded daily for last 3 months was 219.56K.
The market value of GRTX currently stands at $2.61M with its latest stock price at $0.05 and 54.39M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com